TrialLeukemia2020
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Jan A Burger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
273 papers cite itlatest 60 shown
this paperpooled ittrialcites it